Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

GATA2 Deficiency: Early Identification for Improved Clinical Outcomes

Kristen Cole
Daniele N. Avila
Mark Parta
Bazetta Blacklock Schuver
Steven M. Holland
Nirali Shah
Dennis Hickstein
CJON 2019, 23(4), 417-422 DOI: 10.1188/19.CJON.417-422

Background: Patients with GATA2 deficiency present with nontuberculous mycobacterial infections, severe viral infections (particularly refractory human papillomavirus disease), lymphedema, myelodysplastic syndrome (MDS), and acute myeloid leukemia. Patients with GATA2 deficiency who undergo allogeneic hematopoietic stem cell transplantation prior to the development of life-threatening infections or cytogenetic abnormalities may have optimal clinical outcomes.

Objectives: The aim of this article is to determine ways in which oncology nurses can identify GATA2 deficiency in patients early and optimize treatment decisions.

Methods: A case study is presented of a 33-year-old man with recurrent infections and MDS and his two sons, all of whom were found to have the same GATA2 mutation.

Findings: Oncology nurses play an important role in early detection and identification by interviewing patients and obtaining a complete and thorough family history.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or